Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1029 | 1109 | 1212 | 1129 | 1587 | 2918 |
Fund Return | 2.9% | 10.92% | 21.23% | 4.13% | 9.67% | 11.3% |
Place in category | 158 | 139 | 95 | 64 | 57 | 3 |
% in Category | 67 | 63 | 37 | 42 | 31 | 3 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Global Stock Index Ins USD | 19.31B | 5.53 | 8.59 | 8.95 | ||
Global Stock Index Institutional Pl | 19.31B | 5.54 | 8.66 | 9.04 | ||
Global Stock Index Inv USD | 19.31B | 5.53 | 8.59 | 8.92 | ||
US 500 Stock Index Ins USD | 11.81B | 7.01 | 11.30 | 11.98 | ||
US 500 Stock Index Institutional Pl | 11.81B | 7.02 | 11.34 | 12.03 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
US Opportunities Inv USD | 1.31B | 2.89 | 4.02 | 11.19 | ||
US Multi Cap Opportunities Fund UI3 | 341.76M | 1.55 | 8.68 | 10.38 | ||
US Multi Cap Opportunities Fund USD | 341.76M | 1.55 | 8.68 | 10.39 | ||
US Multi Cap Opportunities Fund USI | 341.76M | 1.53 | 8.31 | 9.99 | ||
US Multi Cap Opportunities Fund UID | 341.76M | 1.56 | 8.31 | 10.00 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 6.24 | 735.54 | -2.69% | |
Tesla | US88160R1014 | 3.03 | 181.14 | +0.63% | |
Nextracker | US65290E1010 | 2.96 | 46.10 | +5.54% | |
Flex | SG9999000020 | 2.38 | 27.90 | +1.75% | |
Biomarin Pharma | US09061G1013 | 2.04 | 82.44 | -1.62% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review